Clinical Trials Browser

Laryngeal Diseases × 90 days × Clear all

NCT02128906 2026-04-16

Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

Phase 2 Recruiting

Carcinoma, Squamous Cell, Laryngeal Diseases

NCT07419464 2026-04-09

5-Fluorouracil Response and Optimization STudy (The FROST Trial)

Phase 2 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Laryngeal Diseases

NCT03429036 2026-04-06

Biospecimen Procurement for Head and Neck Disorders

Head and Neck Neoplasms, Hearing Disorders, Laryngeal Diseases, Pharyngeal Neoplasms

NCT06525220 2026-03-27

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

Phase 3 Recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Laryngeal Diseases

NCT06788990 2026-03-23

FORTIFI-HN01

Phase 2/3 Recruiting

Squamous Cell Carcinoma of Head and Neck, Camurati-Engelmann Syndrome, Head and Neck Neoplasms, Laryngeal Diseases

NCT01647477 2026-03-13

DEREDIA

Phase NA Terminated

Laryngeal Diseases

NCT04590963 2026-03-13

INTERLINK-1

Phase 3 Active not recruiting

370 enrolled 21 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Laryngeal Diseases

NCT05199584 2026-03-05

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Phase 2 Completed

CNSDermatologicEndocrineHead & NeckOther solid neoplasmSarcomaThoracic

Uveal Melanoma, Glioma, Adenoma, Islet Cell, Laryngeal Diseases, Medulloblastoma, Melanoma, Mesothelioma, Neuroblastoma, Pituitary Diseases, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma

NCT03656133 2026-02-20

Use of a Proliferation Saturation Index to Determine Personalized Radiotherapy for HPV + Oropharyngeal Cancers

Phase NA Completed

55 enrolled 10 charts

Laryngeal Diseases, Oropharyngeal Neoplasms

NCT05386550 2026-02-19

Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)

Phase 3 Terminated

166 enrolled 15 charts

Head and Neck Neoplasms, Laryngeal Diseases

NCT04368702 2026-02-09

CONFIRM

Phase NA Recruiting

BreastGastrointestinalGenitourinaryHead & NeckLymphoid

Breast Carcinoma In Situ, Urinary Bladder Neoplasms, Laryngeal Diseases, Laryngeal Neoplasms, Lymphoma, Stomach Neoplasms, Lymphoma, Mantle-Cell